ITF2357 was discovered at Italfarmaco of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005.
Adverse effects
In clinical trials of givinostat as a salvage therapy for advanced Hodgkin's lymphoma, the most common adverse reactions were fatigue (seen in 50% of participants), mild diarrhea or abdominal pain (40% of participants), moderate thrombocytopenia (decreased platelet counts, seen in one third of patients), and mild leukopenia (a decrease in white blood cell levels, seen in 30% of patients). One-fifth of patients experienced prolongation of the QT interval, a measure of electrical conduction in the heart, severe enough to warrant temporary suspension of treatment.
It has a size of 100x100x100mm (without antenna) and build around a standard 1U cubesat bus. The primary satellite purpose is the raising awareness of space by providing easily decoded signal to amateur radio receivers. ITF-1's mission was unsuccessful; no signal from the spacecraft was ever received and it reentered to Earth atmosphere on 29 June 2014.
ITF-14 (Interleaved Two of Five) is the GS1 implementation of an Interleaved 2 of 5bar code to encode a Global Trade Item Number. ITF-14 symbols are generally used on packaging levels of a product, such as a case box of 24 cans of soup. The ITF-14 will always encode 14 digits.
GS1GEPIR tool can be used to find out the company identification for a given GTIN-14 that is encoded in ITF-14 Symbol.
The thick black border around the symbol is called the Bearer Bar. The purpose of a Bearer Bar is to equalise the pressure exerted by the printing plate over the entire surface of the symbol, and to enhance reading reliability by helping to reduce the probability of misreads
or short scans that may occur when a skewed scanning beam enters or exits the bar code symbol
through its top or bottom edge.
Uptown is a 2009 independent drama film written and directed by Brian Ackley as his debut feature film, and the second film in the One Way or Another Productions' "Naked Series".
Production
Uptown was shot in an 8 day period with 2 cameras, using only available light and "stolen" Manhattan locations, including scenes that take place in Central Park. After a 2-week production hiatus, it was discovered that one of the cameras had been damaged, rendering everything that was shot on it as unusable. Only a few of those "lost" scenes were reshot.
Actor Chris Riquinha states that he previously worked with producer Princeton Holt on Holt's earlier film Cookies & Cream and that it was Holt who recommended him to writer/director Brian Ackley.
According to the production company, after Uptown won several festival awards, and while the film was still in the festival circuit, the film was picked up for distribution.
Plot
Ben (Chris Riquinha), an aspiring filmmaker, is an unmarried man living in New York. He enjoys the single life but feels his life is missing something. He meets Isabel (Meissa Hampton), a woman unhappy in her marriage who is seeking intimacy. The bond between the two grows as they have repeated liaisons "uptown".
"Uptown" was the lead single in the U.S. to Prince's third album, Dirty Mind. Beginning with a lone drum intro, the track explodes into the keyboards of the chorus. The verses feature a more prominent funkguitar. The song breaks down to a more instrumental section toward the end that mainly consists of guitar, bass and drums with an occasional keyboard riff. The minimalist style of the song is representative of most of the Dirty Mind album. The song addresses the Uptown neighborhood of Minneapolis that was the city's hang-out spot for artists.
Background
The song addresses prejudices and racism, referring to "Uptown" as a metaphor for an ideal place that is free of such things. Prince sings in the first person, and the song opens describing a chance meeting with an attractive woman who then asks in an offensive way if he is gay. The lyrics then rail against prejudice and racism as narrow minded, and exalt in an attitude and spirit that is free of such negativity. It is one of Prince's earliest efforts to blend political statements into his art.
Uptown is a live album by American jazz pianist Billy Taylor featuring tracks recorded in 1960 and released on the Riverside label.
Reception
Allmusic awarded the album 3 stars stating "Although Taylor's activities as a highly articulate spokesman for jazz have sometimes overshadowed his playing, he shows throughout this fine CD reissue that he has long ranked among the best".
Track listing
All compositions by Billy Taylor except as indicated
Distrofia di Duchenne, i dati sulla molecola italiana givinostat
Intervista al Prof. Pier Lorenzo Puri, Professore di pediatria, Università della California a Los Angeles (UCLA)
published: 21 Feb 2016
Webinar - Risultati dello studio clinico con Givinostat nella BMD
Registrazione del webinar del 27 ottobre 2021, nel quale si è parlato dei risultati dello studio clinico di fase 2 con givinostat nella distrofia muscolare di Becker. Ad illustrare i risultati emersi dallo studio e a rispondere alle domande di pazienti e famiglie, il Prof. Giacomo Comi, responsabile del trial presso il Policlinico di Milano.
On April 22, 2020, Italfarmaco joined Parent Project Muscular Dystrophy for a webinar to update the community about Italfarmaco's development of Givinostat and the recent results of the futility analysis of the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
published: 27 Apr 2020
[Webinar] Italfarmaco Provides Givinostat Update - January 2018
Italfarmaco joined PPMD for a webinar on January 24, 2018 to update the Duchenne community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
published: 30 Jan 2018
[Webinar] Italfarmaco Provides Givinostat Update - March 2019
Italfarmaco joined PPMD for a webinar on March 27, 2019 to update the community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Registrazione del webinar del 27 ottobre 2021, nel quale si è parlato dei risultati dello studio clinico di fase 2 con givinostat nella distrofia muscolare di B...
Registrazione del webinar del 27 ottobre 2021, nel quale si è parlato dei risultati dello studio clinico di fase 2 con givinostat nella distrofia muscolare di Becker. Ad illustrare i risultati emersi dallo studio e a rispondere alle domande di pazienti e famiglie, il Prof. Giacomo Comi, responsabile del trial presso il Policlinico di Milano.
Registrazione del webinar del 27 ottobre 2021, nel quale si è parlato dei risultati dello studio clinico di fase 2 con givinostat nella distrofia muscolare di Becker. Ad illustrare i risultati emersi dallo studio e a rispondere alle domande di pazienti e famiglie, il Prof. Giacomo Comi, responsabile del trial presso il Policlinico di Milano.
On April 22, 2020, Italfarmaco joined Parent Project Muscular Dystrophy for a webinar to update the community about Italfarmaco's development of Givinostat and ...
On April 22, 2020, Italfarmaco joined Parent Project Muscular Dystrophy for a webinar to update the community about Italfarmaco's development of Givinostat and the recent results of the futility analysis of the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
On April 22, 2020, Italfarmaco joined Parent Project Muscular Dystrophy for a webinar to update the community about Italfarmaco's development of Givinostat and the recent results of the futility analysis of the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Italfarmaco joined PPMD for a webinar on January 24, 2018 to update the Duchenne community about Italfarmaco's development of Givinostat and currently enrolling...
Italfarmaco joined PPMD for a webinar on January 24, 2018 to update the Duchenne community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Italfarmaco joined PPMD for a webinar on January 24, 2018 to update the Duchenne community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Italfarmaco joined PPMD for a webinar on March 27, 2019 to update the community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 co...
Italfarmaco joined PPMD for a webinar on March 27, 2019 to update the community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Italfarmaco joined PPMD for a webinar on March 27, 2019 to update the community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Registrazione del webinar del 27 ottobre 2021, nel quale si è parlato dei risultati dello studio clinico di fase 2 con givinostat nella distrofia muscolare di Becker. Ad illustrare i risultati emersi dallo studio e a rispondere alle domande di pazienti e famiglie, il Prof. Giacomo Comi, responsabile del trial presso il Policlinico di Milano.
On April 22, 2020, Italfarmaco joined Parent Project Muscular Dystrophy for a webinar to update the community about Italfarmaco's development of Givinostat and the recent results of the futility analysis of the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Italfarmaco joined PPMD for a webinar on January 24, 2018 to update the Duchenne community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
Italfarmaco joined PPMD for a webinar on March 27, 2019 to update the community about Italfarmaco's development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy.
ITF2357 was discovered at Italfarmaco of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005.
Adverse effects
In clinical trials of givinostat as a salvage therapy for advanced Hodgkin's lymphoma, the most common adverse reactions were fatigue (seen in 50% of participants), mild diarrhea or abdominal pain (40% of participants), moderate thrombocytopenia (decreased platelet counts, seen in one third of patients), and mild leukopenia (a decrease in white blood cell levels, seen in 30% of patients). One-fifth of patients experienced prolongation of the QT interval, a measure of electrical conduction in the heart, severe enough to warrant temporary suspension of treatment.